![[U-15N]-ApoE4](https://file.medchemexpress.com/product_pic/hy-187270s.gif "Click to View [U-15N]-ApoE4 Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
apoE4
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "apoE4" in MCE Product Catalog:
6
6 Cited Publications
Cat. No.: HY-N0762
CAS No.: 31524-62-6
1
1 Cited Publications
Target:
Research Areas:
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas .
Cat. No.: HY-176434
CAS No.: 2767324-34-3
Target:
Research Areas:
DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease .
Cat. No.: HY-RS00849
Target:
Research Areas:
APOE Human Pre-designed siRNA Set A contains three designed siRNAs for APOE gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-187270S
Cat. No.: HY-103076R
CAS No.: 1016456-76-0
Target:
Research Areas:
EZ-482 (Standard) is the analytical standard of EZ-482 (HY-103076). This product is intended for research and analytical applications. EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas .
Cat. No.: HY-P700853
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Apolipoprotein E; Apo-E; apoE; apolipo E; apoE4
Cat. No.: HY-P11677
Research Areas:
Cat. No.: HY-P78542A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Apolipoprotein E; Apo-E; apoE; apolipo E; apoE4
Cat. No.: HY-18778C
CAS No.: 866399-89-5
Synonyms: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium
Research Areas:
Obicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
